Clinical Relevance
The clinical relevance of research is an important consideration. There has been agreement since Nuremberg that research should be designed to "yield fruitful results for the good of society." 1 In considering whether a placebo control would be ethically permissible, Sir A Bradford Hill, who introduced the modern era of clinical trials, suggested that when there is already available "an orthodox treatment of proved or accepted value…the question hardly arises, for the doctor will wish to know whether a new treatment is more, or less, effective than the old, not that it is more effective than nothing." 2 One can question the clinical utility of knowing absolute efficacy (for example, the drug is better than no treatment), compared with comparative efficacy (the drug is as good as-or better than-others available to the clinician).
Hill's statement reflects the same concern asserted in requiring that a study must begin with an honest null hypothesis: genuine medical uncertainty concerning the relative merits of the various treatment arms included in a trial's design. 3 Wasting resources or putting participants at risk without the possibility of acquiring valuable knowledge raises serious ethical concerns.
Scientific Validity
Some argue that placebo and not active controls are necessary to determine whether an unproven treatment has assay sensitivity, that it is in fact effective. 4 However, in practice, there are obstacles to the assurance of assay sensitivity, even with active controls. One serious difficulty with placebocontrolled trials is inattention to the importance of blinding. Any argument relying on the superiority of having a placebo arm requires that neither those running the trial nor the participants can tell who is on an active control and who is receiving a placebo. However, many trials provide no commentary on blinding in their published results. 5 Further, arguments supporting the necessity of placebo controls for scientific rigour lead inescapably to the conclusion that active controlled trials in such areas as infection control or oncology, which frequently use placebo as an add-on, may result in the approval of inferior therapies because of the inability to use a placebo control. These issues seriously undermine the arguments that trials require a placebo control for scientific or methodological rigour. While potentially raising feasibility issues, many of the scientific validity problems cited in the literature can be overcome by designing larger trials, as opposed to leaving participants untreated.
Ethical Issues
Even if placebo controls were required for methodological rigour, this would not in itself make such trials ethical. Scientific validity is a necessary but insufficient requirement for ethical trials. Research must also respect the participant's interests. Codes of medical ethics are clear that the patient's well-being is the physician's primary concern. Some argue otherwise. They make appeals to liberty, arguing patient autonomy to choose trial participation. They distinguish research from clinical care by their different objectives. The former, they state, is designed to answer a research question, while the latter is intended to provide care in the patient's interest. The result is a claim that the ethics of the traditional physician-patient relationship do not apply to research because a clinical trial is not a form of therapy. Consequently, they allege, the investigator's obligation is only one of not exploiting research participants by exposing them to excessive risk, as opposed to acting in their best interests. 6 However, saying one does not have a therapeutic obligation does not make it so. This is particularly clear when physicianinvestigators are in a treating relationship with patientparticipants. This situation is recognized in the Declaration of Helsinki, which states that "In medical research on human subjects, considerations related to the well-being of the human subject should take precedence over the interests of science and society." 7 The Canadian Medical Association's Code of Ethics is typical of many others in listing the first Fundamental Responsibility of Physicians as, "Consider first the well-being of the patient." 8 As a normative matter, this obligation defines ethical trial design by prohibiting any compromise of a patient's entitlement to medical treatment by enrolling in a study.
Some propose that limitations on risk of harm make use of placebo controls permissible. No one argues that there are no cases in which a placebo-controlled trial would be ethically acceptable. For example, placebo controls would be appropriate in cases where there was no established effective therapy, or where the standard was shown to be no better than placebo, or where there was evidence creating substantial doubt regarding the net therapeutic advantage of standard therapy. Some justify placebo use claiming that subjects assigned to a placebo group do not suffer real or serious harm, or that the trials are short and deteriorating participants will be withdrawn from the trial. There are at least 3 responses to such arguments: cases of harm from failure to treat or failure to withdraw trial participants have been well documented 9 ; withdrawing deteriorating patients from a trial ignores the inconvenience or harm experienced before withdrawal; and conducting clinical trials should not be an invitation to practice substandard medicine. Those arguing this kind of containment of risk ignore the duty to treat that underpins not only the Hippocratic oath but also the Declaration of Helsinki. Competent psychiatric practice does not consider the duty to patients discharged at the point where suicide is averted, ignoring other kinds of suffering and loss that patientparticipants in such trials might experience.
Legal Perspectives
Those supporting the use of placebo controls where there is an established, effective therapy ignore questions of potential legal liability for harm to patients who participate in such trials. Common-law principles of legal liability and relevant American and Canadian nonplacebo research cases provide the basis for a sound legal argument that research participants harmed by the denial of established, effective treatment in the placebo arm of a trial might have an action in negligence against the physician-investigator. 9 This will depend on whether the investigator is in a doctorpatient relationship, thus owing the patient a duty of care. In other words, did the physician-investigator hold him or herself out as ready and willing to diagnose, treat, or refer the patient-participant? Physicians themselves acknowledge the existence of this relationship when they are involved in research to test treatment. The American Medical Association's Code of Medical Ethics 10 states that in research designed to test the efficacy of treatment, the investigator "must recognize that the physician-patient relationship exists and that professional judgment and skill must be exercised in the best interest of the patient."
Physicians have both an ethical and a legal fiduciary relationship with their patients. As fiduciaries, they must not allow their own interests to conflict with their patients' best interests. A physician may be receiving financial benefits to recruit or conduct a clinical trial. There are also professional rewards, such as publications, promotion, and high regard from peers for conducting research. The investigator's other interests create the potential for conflict with duties to the patient. Trials are not designed with a placebo arm to benefit the patients in that trial. They are designed for the benefit of others, whether future patients, pharmaceutical sponsors, investors, or others. Therefore, a patient in the placebo arm of a clinical trial whose condition deteriorates from lack of treatment may have a cause of action for breach of fiduciary duty if other interests are put above those of the patient. 
Conclusion
Clinical and scientific arguments for the use of placebo controls, when there is established effective therapy, are unconvincing and conflict with recognized ethical and legal obligations. Further, physicians who are investigators cannot waive their obligations toward patients who participate in clinical trials. Participating in trials should never require the practice of substandard medicine or disadvantage patients.
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